ABSTRACT. In two previous reports, we have demonstrated that injection of bee venom (BV) into an acupoint produces a significant antinociceptive and anti-inflammatory effect in both a mouse model of visceral nociception and a rat model of chronic arthritis. Th e present study was designed to evaluate the potential antinociceptive effect of BV pretreatment on formalin-induced pain behavior and it associated spinal cord Fos expression in rats. Adult Sprague-Dawley rats were injected with BV directly into the Zusanli (ST36) acupoint or into an arbitrary non-acupoint located on the back. BV pretreatment into the Zusanli acupoint significantly decreased paw-licking time in the late phase of the formalin test. In contrast, BV injected into a non-acupoint in the back region did not suppress the paw-licking time. In addition, BV pretreatment into the Zusanli acupoint markedly inhibited spinal cord Fos expression induced by formalin injection. These findings indicate that BV pretreatment into the Zusanli acupoint has an antinociceptive effect on formalin-induced pain behavior. Bee venom (BV) from the honeybee consists of melittin, phospholipase A 2 , apamin, adolapin, mast cell degranulating peptide and several other bioactive substances [26] . Melittin and phospholipase A 2 , two major components of BV, are generally thought to play an important role in the induction of the irritation and allergic reaction associated with the bee stings. In this regard, intradermal injection of melittin produces a local hyperthermic effect in human [23] . Phospholipase A 2 is a membrane-associated phospholipid converting enzyme that is important in the production of arachidonic acid. Arachidonic acid is further metabolized by one of two enzyme pathways into various prostaglandins (by cyclooxygenase) or leukotrienes (by lipooxygenase). Subcutaneous BV injection into plantar surface of the rat paw produces characteristic pain behaviors including paw licking and flinching [26] while BV administration in cats has been shown to produce prolonged and tonic nociceptive responses associated with changes in the firing of spinal cord neurons [7] . Chen and his colleagues have since published several reports that have elucidated some of the mechanisms underlying BV-induced nociception in rats and cats [7-13, 27, 28, 34, 35].
Bee venom (BV) from the honeybee consists of melittin, phospholipase A 2 , apamin, adolapin, mast cell degranulating peptide and several other bioactive substances [26] . Melittin and phospholipase A 2 , two major components of BV, are generally thought to play an important role in the induction of the irritation and allergic reaction associated with the bee stings. In this regard, intradermal injection of melittin produces a local hyperthermic effect in human [23] . Phospholipase A 2 is a membrane-associated phospholipid converting enzyme that is important in the production of arachidonic acid. Arachidonic acid is further metabolized by one of two enzyme pathways into various prostaglandins (by cyclooxygenase) or leukotrienes (by lipooxygenase). Subcutaneous BV injection into plantar surface of the rat paw produces characteristic pain behaviors including paw licking and flinching [26] while BV administration in cats has been shown to produce prolonged and tonic nociceptive responses associated with changes in the firing of spinal cord neurons [7] . Chen and his colleagues have since published several reports that have elucidated some of the mechanisms underlying BV-induced nociception in rats and cats [7-13, 27, 28, 34, 35] .
In contrast to this recent focus on BV's nociceptive effects, Kwon and his co-workers have reported that longterm treatment with BV at a dose of 1 mg/kg/day produces a significant antinociceptive and anti-inflammatory effect on the Freund's complete adjuvant-induced arthritis in rats [24] . Although natural BV produces irritation when injected subcutaneously, injection of diluted BV, particularly into an acupoint, can reduce chronic nociception and inflammation. Thus Kwon et al. have shown that BV treatment into an acupoint can significantly reduce arthritisassociated edema and nociceptive responses [24] . In addition, BV injection into the Zhongwan acupoint significantly reduces the number of abdominal stretches induced by intraperitoneal acetic acid injection and also reduces neuronal Fos expression in the spinal cord dorsal horn and nucleus tractus solitarii in mice [25] . In this latter study, BV treatment into a non-acupoint (i.e. on the back) failed to produce this antinociceptive effect except at the highest dose (2.5 mg/kg) tested.
In oriental medicine, acupuncture is one of the most common therapies used to treat a number of human inflammatory diseases including rheumatoid arthritis [3] and osteoarthritis [16] . Depending upon the type of acupoint stimulation, acupuncture can be classified into acupressure, manual acupuncture, electroacupuncture and moxibustion. Generally, it is believed that the analgesic effect of acupuncture is due to activation of the descending pain modulating system [21] . Acupoint stimulation is thought to activate primary afferent fibers which in turn stimulate ascending pathways that ultimately activate the descending pain modulating system including the periaqueductal grey (PAG), raphe magnus (RMg) and the locus coeruleus (LC). Endogenous opioids such as enkephalin and monoamines, such as serotonin are known to be important mediators of acupuncture analgesia [14] . In this regard acupuncture analgesia is completely abolished in cats and mice by the injection of naloxone, a non-selective opioid antagonist [30, 31] . This suggests that acupuncture analgesia is mediated by endogenous opioid components of the descending pain modulating system. In addition, serotonin and norepinephrine are also known to be important neurochemical components involved in acupuncture analgesia [21, 33] .
The formalin test is one of a number of widely used acute pain models [2, 15, 32] . Injection of diluted formalin into the plantar or dorsal surface of the paw produces a biphasic series of pain behaviors that included paw licking, biting, shaking, and flinching. Formalin-induced pain behavior is typically divided into two components (i.e. an early neuronal phase extending from the time of formalin injection to 10 min postinjection and a late inflammatory phase extending from 10 min to 1 hr). Moreover, the noxious input to the spinal cord resulting from formalin injection significantly increases spinal cord Fos expression [22] . Morphine [5] as well as electroacupuncture [6] reduces spinal Fos expression that was elevated by noxious stimulation. These results are consistent with a large body of literature indicating that spinal cord neuronal Fos protein expression can be used as an indicator of nociception.
The aim of this study was to determine whether BV administration has a suppressive effect on formalin-induced pain behavior and spinal Fos expression. In addition, we compared the antinociceptive effect of BV injection into the Zusanli acupoint with that obtained following injection into a non-acupoint.
MATERIALS AND METHODS

Animals:
Experiments were performed on male Sprague Dawley rats weighing 200-250 g. All experimental animals were obtained from the Laboratory Animal Center of Seoul National University. They were housed in colony cages with free access to food and water. They were maintained in temperature and light controlled rooms (23 ± 0.5°C, 12/12 hr/light/dark cycle with lights on at 07:00) for at least 1 week prior to the study. All of the methods used in the present study were approved by the Animal Care and Use Committee at SNU and conform to NIH guidelines (NIH publication No. 86-23, revised 1985). The ethical guidelines of the International Association for the Study of Pain [36] for investigating experimental pain in conscious animals was also followed.
Drug treatment: BV of Apis mellifera (Sigma, St. Louis, MO, U.S.A.) at doses of 0.0016, 0.008, 0.016 and 0.08 mg/ kg was dissolved in physiological saline solution (20 µl) and subcutaneously administered into the Zusanli acupoint located 5 mm lower and lateral to the anterior tubercle of tibia. A vehicle control group received an injection of a corresponding volume of saline solution into the same acupoint. The highest dose of BV (0.08 mg/kg) was used to compare the antinociceptive effects of injection into an acupoint with injection into a non-acupoint. To evaluate this, BV was injected into the Zusanli acupoint in one group of animals and into an arbitrary site located on the back (nonacupoint) in another group of rats 30 min prior to formalin injection.
Formalin test: Thirty minutes after BV injection, 1% formalin (0.37% formaldehyde) in a volume of 20 µl was injected subcutaneously into the plantar surface of the right hindpaw with a 30-G needle. Following formalin injection, the animals were placed in a temperature regulated plexiglas observation chamber. A mirror was attached underneath the chamber and was set at a 45° angle to allow an unimpeded view of the animals' paws. Behavioral responses were then recorded using a video recording system. To access formalin-induced pain behavior, paw licking time was measured every 5 min during a 60 min post-injection period. Pawlicking time was divided into two components (i.e. an early neuronal phase extending from the time of formalin injection to 10 min, phase 1 and a late inflammatory phase extending from 10 min to 60 min, phase 2) and analyzed [15] . All behaviors were analyzed on the recorded videotapes by an observer who was blinded to the treatment group.
Fos immunohistochemistry: All procedures used in the present study are based on those described previously by Kwon et al. [24, 25] . Animals were perfused with calciumfree tyrode's solution followed by a fixative containing 4% paraformaldehyde and 0.2% picric acid in 0.1 M phosphatebuffered saline (PBS, pH 6.9). Specimen was post-fixed by same fixative overnight and cryoprotected with 30% sucrose in PBS and sectioned on a cryostat (Microm, Germany). After elimination of endogenous peroxidase activity and preblocking with normal goat, the sections were incubated in polyclonal rabbit anti-Fos antiserum (Calbiochem, 1:10,000). The sections were processed with the avidinbiotin-peroxidase technique as previously described [24, 25] . Finally, Fos positive neurons were visualized using 3,3'-diaminobenzidine (DAB, Sigma Chemical Co., St. Louis, Mo, U.S.A.). Immunohistochemical controls consisted of sections incubated without primary or secondary antibodies.
Cell counting and image analysis: The selected sections were digitized with 4096 gray levels using a cooled CCD (Micromax Kodak 1317, Princeton instrument, U.S.A.) equipped with a computer-assisted image analysis system (Metamorph, Universal Imaging Co. U.S.A.). All data analysis procedures were performed blindly with respect to the experimental condition of the animal. To assess the effect of BV pretreatment on Fos expression in spinal neurons, four regions of the spinal cord were selected for examination based on cytoarchitectonic criteria. These four regions included the superficial lamina of the dorsal horn (SDH, lamina I-II), nucleus proprius (NP, lamina III-IV), the neck region of dorsal horn (NECK, lamina V-VI) and the ventral horn (VENT, lamina VII-IX).
Statistical analysis: One-way ANOVA was performed to determine the overall effect of BV pretreatment on formalin induced pain related behavior and on spinal Fos expression. Unpaired t-tests were used to determine the p value when ANOVA indicated a significant group difference. A p value <0.05 was considered statistically significant and all values are expressed as the mean ± SEM.
RESULTS
Dose dependent effect of acupoint BV pretreatment on formalin-induced pain behavior:
In the early acute phase, BV injection into the Zusanli acupoint at doses of 0.0016, 0.008, and 0.016 did not suppress formalin-induced pain behavior (Fig. 1A and B) . Only the highest dose of BV significantly decreased the paw locking time in the early phase. In contrast during the late phase, BV injection in the Zusanli acupoint suppressed paw-licking time in a dose dependent manner. However, pretreatment with the lowest dose of BV (0.0016 mg/kg) failed to inhibit pain behaviors during the late phase.
Site comparison study: Based on the above results, the most effective dose of BV (0.08 mg/kg) was selected and then utilized for the acupoint versus nonacupoint comparison study. In the early phase, BV pretreatment into a nonacupoint on the back failed to block formalin-induced pain behavior (Fig. 2) . In contrast, BV injection into the Zusanli acupoint reduced paw licking time during phase 1 (* p<0.05). Moreover, BV pretreatment into the Zusanli acupoint also significantly suppressed formalin-induced paw licking time during the late phase (*** p<0.001). BV pretreatment into an arbitrary site on the back (BV/back-Formalin) on the other hand showed no suppressive effect on Figs. 3 and 4) in the salinesaline group. In the BV-saline treatment group, there was a slight but reproducible increase in the number of Fos positive neurons when compared with that of the saline-saline group, but this increase was not statistically significant. In the saline-formalin treatment group, Fos expression was significantly increased in every region of the lumbar spinal cord as compared with the saline-saline group (** p<0.01). In contrast, BV pretreatment significantly decreased formalin-induced spinal Fos expression in the BV-formalin group as compared to saline pretreatment in the saline-formalin group (* p<0.05 and ** p<0.01, respectively).
DISCUSSION
Suppressive effect of BV pretreatment on formalininduced pain behavior:
It is well established that the early (acute) phase of formalin-induced pain behavior is produced by direct activation of primary afferent fibers, while pain behaviors associated with the late phase are associated with formalin-induced inflammatory reaction [31] . In the present study, we have shown that BV pretreatment at doses of 0.0016, 0.008, and 0.016 mg/kg did not reduce formalininduced paw licking time during the early phase (Fig. 1A  and B) . However the highest dose of BV (0.08 mg/kg) did suppress formalin-induced pain behavior during the early phase. In the late phase of the formalin test, BV pretreatment into the Zusanli acupoint produced a dose dependent reduction of formalin-induced paw licking time, except at the lowest dose tested (0.0016 mg/kg). Previously, Kwon and his co-workers demonstrated that BV administration produced both an antinociceptive and an anti-inflammatory effect on the acetic acid-induced writhing reflex in mice and on complete Freund's adjuvant-induced arthritis in rats [24, 25] . Based on these previous findings, we hypothesized that BV injected into an acupoint might behave as a chemical stimulant that activates the acupoint and subsequently engages the endogenous pain modulating system. Because whole BV contains stimulating components such as melittin and phospholipase A 2 , it is possible that these stimulating components may activate the acupoint directly. Furthermore, we assumed that the antinociceptive effect of BV was from the melittin because it is major component of whole BV (50% of dried BV) [26] . Thus we would propose that BV pretreatment into an acupoint produces its antinociceptive effect on formalin-induced pain by ultimately activating the endogenous pain modulation system. In the early phase, the highest dose of BV (0.08 mg/kg) suppressed the formalin-induced paw licking time, however lower doses of BV did not suppress this formalin-induced pain. This data would imply that the highest dose of BV was potent enough to rapidly activate the descending pain modulating system. However, lower doses of BV failed to produce the inhibitory effect on paw licking time in phase 1.
In the late phase (phase 2), BV pretreatment into the Zusanli acupoint produced a dose dependent suppressive effect on formalin-induced pain behavior (except at the lowest dose of BV tested, 0.0016 mg/kg). This low dose of BV might not be at a sufficient concentration to activate primary afferents and ultimately engage the descending pain modulating system. Acupuncture treatment has been reported to release enkephalin and dynorphin at the spinal cord level and these peptides are thought to directly inhibit afferent nociception [21] . Moreover acupuncture-evoked enkephalin release at midbrain levels is postulated to activate descending systems. These descending systems release serotonin and norepinephrine at the spinal cord level, which in turn block afferent pain transmission. Therefore it is possible that BV injection into an acupoint serves to activate descending systems that modulate nociceptive input at spinal cord levels via opioid, adrenergic and/or serotonergic mechanisms. In this regard a recent study of Kwon et al. [25] demonstrates that the antinociceptive effect of BV injected into Zhongwan acupoint on abdominal stretches is mediated by the α 2 adrenergic system. However, further investigation is still necessary to elucidate the antinociceptive mechanisms induced by BV in the formalin test.
Acupoint vs non-acupoint stimulation: Kwon et al. reported that the BV injection into an acupoint produces a more potent antinociceptive effect than BV injection into a non-acupoint on the acetic acid-induced writhing reflex in mice [25] . It has also been reported that electroacupuncture (EA) stimulation of the Hoku acupoint suppresses tooth pulp stimulation-induced stress in rats [18] . In this latter study EA was administered to animals in the stressed state and the EA treated animals showed very little change in blood pressure compared to animals that were stressed but received EA in a non-acupoint on the tail. In addition, the EA treated animals had significantly lower blood levels of ACTH and corticosterone and the stress-induced cathecholamines norepinephrine, epinephrine and dopamine compared to the EA/non-acupoint treated group. In the present study we showed that BV injection into the Zusanli acupoint at the three highest doses tested produced a significant suppressive effect on pain behavior in the late phase of the formalin test. Conversely, BV pretreatment into a nonacupoint located on the back did not suppress the formalininduced pain behavior (Fig. 2) . As alluded to above, we hypothesized that BV administration into an acupoint may activate the acupuncture-related neural circuit and through this activation, BV might produce its antinociceptive effect on formalin-induced pain behavior. We conclude from these results that the antinociceptive effect of BV is only produced when BV is administered into a specific acupoint.
The effect of BV on spinal Fos expression and correlation relationship: It has been reported that peripheral noxious and non-noxious (tactile) stimulation increases Fos expression in a corresponding region of the spinal cord [22] . After the discovery that this immediate early gene could be used as a marker of nociceptive-related neurons, Fos protein has been used extensively to study spinal cord regions activated by nociception [19] . Gogas et al. [17] have previously demonstrated that formalin injection into plantar surface of hindpaw dramatically increases the spinal Fos expression and that intracerebroventricular injection of morphine dose dependently reduces spinal Fos expression in a naloxone reversible manner. Analgesic drugs such as dexamethasone [4] and aspirin [20] have also been shown to reduce spinal Fos expression induced by nociceptive stimuli.
In the present study, we divided the spinal cord into four regions (based in part on afferent fiber termination patterns) to allow regional quantitative analysis of Fos expression (Figs. 3 and 4) . Among these four regions, the superficial dorsal horn has been shown to be an important area related to nociceptive processing in the formalin test [1] . Intraplantar injection of formalin dramatically increased spinal cord Fos expression. BV pretreatment into the Zusanli acupoint (BV-formalin) significantly suppressed the Fos expression that was evoked by formalin injection (Fig. 3) . We initially hypothesized that BV injection alone would cause increased Fos expression in the spinal cord. Although Fos expression was slightly increased in the BV-saline group, there was no statistical difference as compared with that of the salinesaline group (Fig. 3) . Thus if BV treatment is activating normal acupuncture related antinociceptive pathways in the central nervous system, the spinal involvement in this activation is not evident in Fos reacted spinal cords.
In this study, we provided evidence that BV pretreatment into the Zusanli acupoint suppresses formalin-induced pain behavior. In contrast BV treatment into a non-acupoint located on the back did not produce antinociceptive effects on formalin-induced pain behaviors. In addition, BV pretreatment into the Zusanli acupoint significantly suppressed spinal cord Fos expression evoked by formalin injection. These results suggest that BV injection into the Zusanli acupoint has an antinociceptive effect on formalin-induced pain.
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